Cargando…

Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?

Detalles Bibliográficos
Autores principales:	Castellano, Gina M., Pine, Sharon R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481585/ https://www.ncbi.nlm.nih.gov/pubmed/32953473 http://dx.doi.org/10.21037/tlcr.2020.04.05

Ejemplares similares

Drying nano particles solution on an oscillating tip at an air liquid interface: what we can learn, what we can do
por: Bernard, Charlotte, et al.
Publicado: (2007)

What can we learn from a COVID-19 lung biopsy?
por: Wu, Jinxiang, et al.
Publicado: (2020)

How Well Can We Infer Selection Benefits and Mutation Rates from Allele Frequencies?
por: Soriano, Jonathan, et al.
Publicado: (2023)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?
por: Mocan, Tudor, et al.
Publicado: (2020)

Liquid biopsies, are we ready for prime time?
por: Normanno, Nicola, et al.
Publicado: (2023)

Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
por: Kato, Shumei, et al.
Publicado: (2022)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Phytic Acid and Transporters: What Can We Learn from low phytic acid Mutants?
por: Cominelli, Eleonora, et al.
Publicado: (2020)

What Can We Demonstrate?
por: Mills, G. A.
Publicado: (1896)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Enhancer RNA: What we know and what we can achieve
por: Han, Zhenzhen, et al.
Publicado: (2022)

What we can and what we cannot see with extracellular multielectrodes
por: Chintaluri, Chaitanya, et al.
Publicado: (2021)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

Can double PPO mutations exist in the same allele and are such mutants functional?
por: Porri, Aimone, et al.
Publicado: (2022)

Liquid Biopsy: Current Status and Future Perspectives
por: Baev, Vesselin, et al.
Publicado: (2023)

Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today
por: Borawski, Bartłomiej, et al.
Publicado: (2021)

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)

Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
por: Minciacchi, V R, et al.
Publicado: (2017)

Assessment practices in undergraduate clinical medicine training: What do we do and how can we improve?
por: Brits, Hanneke, et al.
Publicado: (2020)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results
por: McCord, Matthew, et al.
Publicado: (2023)

Frequency of the MDR1 mutant allele associated with multidrug sensitivity in dogs from Brazil
por: Monobe, Marina M, et al.
Publicado: (2015)

Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency
por: Cole, Alexander J., et al.
Publicado: (2017)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
por: Mazzitelli, Carlotta, et al.
Publicado: (2023)

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
por: Mondelo-Macía, Patricia, et al.
Publicado: (2021)

Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?
por: van der Laan, Pia, et al.
Publicado: (2021)

Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
por: Heredia-Soto, Victoria, et al.
Publicado: (2021)

Liquid Biopsy in Gastrointestinal Cancers: How Close Are We to Reaching the Clinic?
por: Earl, Julie, et al.
Publicado: (2023)

What can we teach Lymnaea and what can Lymnaea teach us?
por: Rivi, Veronica, et al.
Publicado: (2021)

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
por: Rompianesi, Gianluca, et al.
Publicado: (2021)

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies
por: Nunes, Sandra P., et al.
Publicado: (2019)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Management of Achilles and patellar tendinopathy: what we know, what we can do
por: Aicale, Rocco, et al.
Publicado: (2020)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Hepatitis of unknown etiology in children: What we know and what we can do?
por: Zhu, Mingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0fobptshmq06akac6hk6b6bd3h